Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide

Brain Research Bulletin

Volumn 87, Issue 6, 2012, Pages 544-550

  Shafaroodi, Hamed ^a   Moezi, Leila ^b   Ghorbani, Hassan ^b   Zaeri, Meysam ^b   Hassanpour, Sara ^a   Hassanipour, Mahsa ^a   Dehpour, Ahmad Reza ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti convulsant; Mice; Nitric oxide; Pentylenetetrazole; Pioglitazone

Indexed keywords

AMINOGUANIDINE; ANTICONVULSIVE AGENT; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PENTETRAZOLE; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLONIC SEIZURE; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PENTYLENETETRAZOLE; SEIZURES; THIAZOLIDINEDIONES;

EID: 84859159426     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.02.001     Document Type: Article

References (56)

1. Abdallah D.M. Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res. 2010, 1351:246-253.
2. Akbas S.H., Yegin A., Ozben T. Effect of pentylenetetrazol-induced epileptic seizure on the antioxidant enzyme activities, glutathione and lipid peroxidation levels in rat erythrocytes and liver tissues. Clin. Biochem. 2005, 38:1009-1014.
3. Allami N., Javadi-Paydar M., Rayatnia F., Sehhat K., Rahimian R., Norouzi A., Dehpour A.R. Suppression of nitric oxide synthesis by l-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur. J. Pharmacol. 2011, 650:240-248.
4. Banach M., Piskorska B., Czuczwar S., Borowicz K. Nitric Oxide epileptic seizures and action of antiepileptic drugs. CNS Neurol Disord. Drug Targets 2011.
5. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
6. Buisson A., Lakhmeche N., Verrecchia C., Plotkine M., Boulu R.G. Nitric oxide: an endogenous anticonvulsant substance. Neuroreport 1993, 4:444-446.
7. Desvergne B., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol. 2004, 18:1321-1332.
8. Dillioglugil M.O., Kir H.M., Demir C., Ilbay G., Sahin D., Dillioglugil O., Bambal G., Mekik H., Ates N. Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels, and SOD activities in rat liver and kidney tissues. Brain Res. Bull. 2010, 83:356-359.
9. Forst T., Hanefeld M., Pfutzner A. Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin. Pharmacother. 2011, 12:1571-1584.
10. Goya K., Sumitani S., Otsuki M., Xu X., Yamamoto H., Kurebayashi S., Saito H., Kouhara H., Kasayama S. The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J. Diabetes Complications 2006, 20:336-342.
11. Homayoun H., Khavandgar S., Dehpour A.R. Anticonvulsant effects of cyclosporin A on pentylenetetrazole-induced seizure and kindling: modulation by nitricoxidergic system. Brain Res. 2002, 939:1-10.
12. Homayoun H., Khavandgar S., Namiranian K., Gaskari S.A., Dehpour A.R. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. 2002, 48:33-41.
13. Huang C.W., Tsai J.J., Ou H.Y., Wang S.T., Cheng J.T., Wu S.N., Huang C.C. Diabetic hyperglycemia is associated with the severity of epileptic seizures in adults. Epilepsy Res. 2008, 79:71-77.
14. Huang P.H., Sata M., Nishimatsu H., Sumi M., Hirata Y., Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed. Pharmacother. 2008, 62:46-52.
15. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
16. Khavandgar S., Homayoun H., Dehpour A.R. Mediation of nitric oxide in inhibitory effect of morphine against electroshock-induced convulsions in mice. Pharmacol. Biochem. Behav. 2003, 74:795-801.
17. Kielian T., Syed M.M., Liu S., Phulwani N.K., Phillips N., Wagoner G., Drew P.D., Esen N. The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. J. Immunol. 2008, 180:5004-5016.
18. Kim K.Y., Cho H.S., Lee S.H., Ahn J.H., Cheon H.G. Neuroprotective effects of KR-62980 a new PPARgamma agonist, against chemical ischemia-reperfusion in SK-N-SH cells. Brain Res. 2011, 1372:103-114.
19. Koltai M., Minker E. Changes of electro-shock seizure threshold in alloxan diabetic rats. Experientia 1975, 31:1369.
20. Kumar P., Kaundal R.K., More S., Sharma S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav. Brain Res. 2009, 197:398-403.
21. Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia 2001, 42(Suppl. 4):7-12.
22. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. 2001, 90:21-34.
23. Lallement G., Shih T.M., Pernot-Marino I., Baubichon D., Foquin A., McDonough J.H. The role of nitric oxide in soman-induced seizures, neuropathology, and lethality. Pharmacol. Biochem. Behav. 1996, 54:731-737.
24. Li D., Chen K., Sinha N., Zhang X., Wang Y., Sinha A.K., Romeo F., Mehta J.L. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc. Res. 2005, 65:907-912.
25. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991, 8:171-189.
26. McHugh J.M., McHugh W.B. Diabetes and peripheral sensory neurons: what we don't know and how it can hurt us. AACN Clin. Issues 2004, 15:136-149.
27. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329:2002-2012.
28. Moraes L.A., Piqueras L., Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 2006, 110:371-385.
29. Mrak R.E., Landreth G.E. PPARgamma, neuroinflammation, and disease. J. Neuroinflammation 2004, 1:5.
30. Mulsch A., Busse R., Mordvintcev P.I., Vanin A.F., Nielsen E.O., Scheel-Kruger J., Olesen S.P. Nitric oxide promotes seizure activity in kainate-treated rats. Neuroreport 1994, 5:2325-2328.
31. Nidhi G., Balakrishnan S., Pandhi P. Role of nitric oxide in electroshock and pentylenetetrazole seizure threshold in rats. Methods Find. Exp. Clin. Pharmacol. 1999, 21:609-612.
32. Obay B.D., Tasdemir E., Tumer C., Bilgin H.M., Atmaca M. Dose dependent effects of ghrelin on pentylenetetrazole-induced oxidative stress in a rat seizure model. Peptides 2008, 29:448-455.
33. Okada K., Yamashita U., Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 2006, 1102:175-178.
34. Osonoe K., Mori N., Suzuki K., Osonoe M. Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazol-induced seizures in rats. Brain Res. 1994, 663:338-340.
35. Patsoukis N., Zervoudakis G., Georgiou C.D., Angelatou F., Matsokis N.A., Panagopoulos N.T. Thiol redox state and lipid and protein oxidation in the mouse striatum after pentylenetetrazol-induced epileptic seizure. Epilepsia 2005, 46:1205-1211.
36. Raghavendra S., Ashalatha R., Thomas S.V., Kesavadas C. Focal neuronal loss, reversible subcortical focal T2 hypointensity in seizures with a nonketotic hyperglycemic hyperosmolar state. Neuroradiology 2007, 49:299-305.
37. Russell J.W., Sullivan K.A., Windebank A.J., Herrmann D.N., Feldman E.L. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol. Dis. 1999, 6:347-363.
38. Sadaghiani M.S., Javadi-Paydar M., Gharedaghi M.H., Fard Y.Y., Dehpour A.R. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway. Behav. Brain Res. 2011, 224:336-343.
39. Sahin D., Ilbay G., Ates N. Changes in the blood-brain barrier permeability and in the brain tissue trace element concentrations after single and repeated pentylenetetrazole-induced seizures in rats. Pharmacol. Res. 2003, 48:69-73.
40. Sardo P., D'Agostino S., Carletti F., Rizzo V., La Grutta V., Ferraro G. Lamotrigine differently modulates 7-nitroindazole and l-arginine influence on rat maximal dentate gyrus activation. J. Neural Transm. 2008, 115:27-34.
41. Sardo P., D'Agostino S., Rizzo V., Carletti F., Lonobile G., Ferraro G. In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs. J. Neural Transm. 2009, 116:831-839.
42. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 2005, 25:7805-7812.
43. Shah P., Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. 2010, 9:347-354.
44. Siebel A.M., Piato A.L., Capiotti K.M., Seibt K.J., Bogo M.R., Bonan C.D. PTZ-induced seizures inhibit adenosine deamination in adult zebrafish brain membranes. Brain Res. Bull. 2011, 86:385-389.
45. Starr M.S., Starr B.S. Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor l-NAME. Pharmacol. Biochem. Behav. 1993, 45:321-325.
46. Steinman L., Martin R., Bernard C., Conlon P., Oksenberg J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 2002, 25:491-505.
47. Sullivan K.A., Feldman E.L. New developments in diabetic neuropathy. Curr. Opin. Neurol. 2005, 18:586-590.
48. Swinyard E.A., Kupferberg H.J. Antiepileptic drugs: detection, quantification, and evaluation. Fed. Proc. 1985, 44:2629-2633.
49. Talarek S., Fidecka S. Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice. Pol. J. Pharmacol. 2003, 55:181-191.
50. Theard M.A., Baughman V.L., Wang Q., Pelligrino D.A., Albrecht R.F. The role of nitric oxide in modulating brain activity and blood flow during seizure. Neuroreport 1995, 6:921-924.
51. Tomlinson D.R., Gardiner N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008, 9:36-45.
52. Tutka P., Sawiniec J., Kleinrok Z. Experimental diabetes sensitizes mice to electrical- and bicuculline-induced convulsions. Pol. J. Pharmacol. 1998, 50:92-93.
53. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997, 38(Suppl. 1):S9-S17.
54. Wojtal K., Gniatkowska-Nowakowska A., Czuczwar S.J. Is nitric oxide involved in the anticonvulsant action of antiepileptic drugs?. Pol. J. Pharmacol. 2003, 55:535-542.
55. Yahyavi-Firouz-Abadi N., Tahsili-Fahadan P., Riazi K., Ghahremani M.H., Dehpour A.R. Involvement of nitric oxide pathway in the acute anticonvulsant effect of melatonin in mice. Epilepsy Res. 2006, 68:103-113.
56. Yki-Jarvinen H., Thiazolidinediones N. Engl. J. Med. 2004, 351:1106-1118.